Search

Displaying results 2161 - 2170 of 4590 in total
  1. Drug

    Nitrofurantoin

    go.drugbank.com/drugs/DB00698
    ApprovedInvestigationalVet approved

    [L6856,L6859,L6862] Nitrofurantoin is converted by bacterial nitroreductases to electrophilic intermediates which inhibit the citric acid cycle as well as synthesis of DNA, RNA, and protein.

  2. Drug

    Glutethimide

    go.drugbank.com/drugs/DB01437
    ApprovedIllicit

    Its use has been largely superseded by other drugs.

  3. Drug

    Dipyrithione

    go.drugbank.com/drugs/DB11327
    Approved

    Dipyrithione, a bactericidal and fungicidal pyrithione derivate, was formulated as Crimanex anti-dandruff shampoo, but is no longer available. … [L2615] Dandruff is a common scalp disease affecting >40% of the world's adult population, and may be caused by fungi such as _Malassezia globosa_ and _M. restricta_.[A32162]

  4. Drug

    Atrasentan

    go.drugbank.com/drugs/DB06199
    ApprovedInvestigational

    [L52855] In April 2025, atrasentan was granted accelerated approval by the FDA for the reduction of proteinuria in patients with primary IgA nephropathy, becoming the first endothelin A receptor antagonist

  5. Drug

    Xylometazoline

    go.drugbank.com/drugs/DB06694
    Approved

    Xylometazoline works by binding to alpha (α)-adrenergic receptors to cause vasoconstriction of nasal blood vessels.

    Products: NASENSPRAY ELAC 1MG/ML OK
  6. Drug

    Tasonermin

    go.drugbank.com/drugs/DB11626
    Approved

    It was approved for use by the European Medicines Agency in April of 1999 for use as an adjunt to surgery for the subsequent removal of the tumor and in palliative care for irresectable soft tissue sarcoma

  7. Drug

    Seladelpar

    go.drugbank.com/drugs/DB12390
    ApprovedInvestigational

    [L51149] On August 14, 2024, seladelpar was granted accelerated approval by the FDA for the treatment of primary biliary cholangitis,[L51154] which is a condition associated with aberrant bile acid metabolism

  8. Drug

    Voxilaprevir

    go.drugbank.com/drugs/DB12026
    ApprovedInvestigational

    By inhibiting viral protease NS3/4A, voxilaprevir therefore prevents viral replication and function. … Voxilaprevir exerts its antiviral action by reversibly binding and inhibiting the NS3/4A serine protease of Hepatitis C Virus (HCV) [FDA Label].

  9. Drug

    Amifampridine

    go.drugbank.com/drugs/DB11640
    Approved

    Firdapse (amifampridine) was formally approved by the US FDA for the treatment of adults with LEMS as recently as November of 2018 [L4819]. … It was demonstrated in clinical studies involving healthy volunteers that the pharmacokinetics and systemic exposure to amifampridine is affected by the genetic differences in N-acetyl-transferase (NAT

  10. Drug

    Erenumab

    go.drugbank.com/drugs/DB14039
    ApprovedInvestigational

    Aimovig, as released and marketed by Novartis and Amgen, is in fact a novel therapeutic approach as the first and only FDA approved treatment specifically developed to prevent migraine by blocking the